Merck & Co., Inc. (NYSE:MRK) on Tuesday reported its fourth-quarter adjusted earnings per share of $2.04, surpassing consensus estimates of $2.01, a jump from $1.72 a year ago.
Merck reported sales of $16.40 billion, a 5% increase year-over-year, and exceeded the analysts’ projections of $16.19 billion.
Segment And Drug Performance
The pharmaceutical segment recorded $14.84 billion in sales, up 6% year over year, driven by growth in oncology as well as cardiometabolic and respiratory, partially offset by a decline in vaccines.
The Animal Health segment’s revenue of $1.51 billion increased 8% year-over-year, primarily due to higher demand for livestock products.
Keytruda, an immunotherapy for cancer, generated $8.37 billion in global sales, representing a 7% year-over-year …